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ABSTRACT
Introduction: With the current coronavirus disease 2019 (COVID-19) pande-
mic, concerns have been raised about the risk to children with inflammatory bowel
diseases (IBD). We aimed to collate global experience and provide provisional
guidance for managing paediatric IBD (PIBD) in the era of COVID-19.
Methods: An electronic reporting system of children with IBD infected with
SARS-CoV-2 has been circulated among 102 PIBD centres affiliated with
the Porto and Interest-group of ESPGHAN. A survey has been completed by
major PIBD centres in China and South-Korea to explore management
during the pandemic. A third survey collected current practice of PIBD
treatment. Finally, guidance points for practice have been formulated and
voted upon by 37 PIBD authors and Porto group members.
Results: Eight PIBD children had COVID-19 globally, all with mild infection
without needing hospitalization despite treatment with immunomodulators and/
or biologics. No cases have been reported in China and South Korea but biologic
treatment has been delayed in 79 children, of whom 17 (22%) had exacerbation
of their IBD. Among the Porto group members, face-to-face appointments were
often replaced by remote consultations but almost all did not change current IBD
treatment. Ten guidance points for clinicians caring for PIBD patients in
epidemic areas have been endorsed with consensus rate of 92% to 100%.
Conclusions: Preliminary data for PIBD patients during COVID-19 outbreak
are reassuring. Standard IBD treatments including biologics should continue at
present through the pandemic, especially in children who generally have more
severe IBD course on one hand, and milder SARS-CoV-2 infection on the other.
Supplemental digital content: An infographic accompanying this article
can be found at http://links.lww.com/MPG/B842.
Key Words: inflammatory bowel disease, treatment, corona virus disease
2019, Crohn disease, children
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What Is Known
 A global pandemic of coronavirus disease 2019 is
now apparent.
 SARS-CoV-2 infection resulting in coronavirus dis-
ease 2019 causes significant pulmonary disease in
adults leading to intensive care and sometimes
death.
 The impact in adults including on mortality is greater
in patients with chronic diseases.
What Is New
 The first paediatric inflammatory bowel disease
cases to have SARS-CoV-2 infection have been
described.
 Coronavirus disease 2019 in children, including
paediatric inflammatory bowel disease, appears to
be mild.
 Standard paediatric inflammatory bowel disease
treatments should continue since delay in infusions
in endemic areas has been associated with disease
flare.
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C oronavirus disease 2019 (COVID-19) is caused by thezoonotic coronavirus SARS-CoV-2 and started in China
in December 2019 (1). By March 2020, it had been declared by
WHO as a global pandemic. It is predominantly spread by airborne
droplets but there is also viral shedding in stool, giving the potential
for faecal-oral transmission (2,3). In adults, COVID-19 predomi-
nantly presents with cough and fever resulting in a proportion of
patients developing acute respiratory distress syndrome (ARDS)
(4). SARS-CoV-2 infection may also cause gastrointestinal symp-
toms (5,6). The disease course of COVID-19 in children is pre-
dominantly benign with mild or even no symptoms, and almost
no reported mortality (6–8). The severe pulmonary involvement
of the virus may be caused also by hyperinflammation and a
secondary hemophagocytic-lymphohistiocytosis (HLH)-like pre-
sentation (9,10).
SARS-CoV-2 enters cells via the angiotensin-converting
enzyme-2 (ACE-2) receptor that is abundantly expressed in cells
of the lungs, oral cavity, and the gastrointestinal tract. Lymphopenia
and elevated C-reactive protein (CRP), ferritin and lactate dehy-
drogenase levels are associated with a more severe course (11).
Increased levels of cytokines and chemokines, such as interleukin-6
(IL-6), have been associated with increased disease severity in
adults (11) and children (5). It seems that the most severe pre-
sentations of COVID-19 result from hyperinflammatory cytokine
responses in particularly dysregulated IL-6-dependent acute phase
responses associated with a decrease in cytotoxic T and natural
killer (NK) cells. Those findings explain why in addition to antiviral
therapies, immunomodulatory therapies and passive immunisation
strategies could potentially be considered to improve outcome in
severely affected patients (10). Consistent with this hypothesis is
the report that in an endemic area, only 3 children receiving
immunosuppressant medication for liver transplantation developed
SARS-CoV-2 infection and none were severe (12).
The coronaviruses, SARS-CoV and MERS-CoV, were
responsible for previous epidemics. Although clinical and immu-
nological data from these viruses cannot directly be translated to
predict interventions in SARS-CoV-2 infections, it is noteworthy
that thiopurine metabolites, 6-mercaptopurine and 6-thioguanine,
have been shown to have direct antiviral activity by inhibiting the
papain-like protease of both viruses (13) as well as host proteins
involved in antiviral response (14). Systemic steroids, however, did
not confer substantial clinical benefit (15). Indeed, the safety of
corticosteroids during COVID-19 is unclear (16), but it seems that if
used for short periods and at a low dose they are not related to a
worse prognosis, even in patients with COVID-19 pneumonia (17).
There are no published data about the safety of monoclonal anti-
bodies during this infection although anti-IL-6 receptor antibody
has been used in a few patients with COVID-19 with promising
results (18). Current literature related to other viral infections does
not indicate stopping these treatments or modifying therapeutic
regimes (19). In light of the hyperinflammatory immune response
seen in patients with COVID-19 it is highly relevant that blockade
of IL-6R with tocilizumab resulted in clinical improvement associ-
ated with normalisation of fever, lymphocyte counts, and CRP in a
retrospective group of 21 adults with severe SARS-CoV-2 infection
(20). Locally active medications, such as anti-a4b7 (eg, vedolizu-
mab) or budesonide are unlikely to have a major impact on systemic
nor pulmonary SARS-CoV-2 responses.
Despite the above, the IBD-related immunosuppressive treat-
ment has raised concerns regarding the management of COVID-19
with potential implications for treatment, isolation, and routine
hospital attendance (19,21). Provisional reports from adult IBD
centres in China are reassuring (22), and as some of the pulmonary
damage may be caused by autoinflammatory response of the host,
immunosuppressive medication have even been postulated to pro-
tect from severe disease (9,10). Nonetheless, children may have
different recommendations than adults, given the overall milder
course of the infection. In addition, IBD in children tends to be more
extensive and severe than adults with consistently higher need for
immunomodulators and biologics. We thus aimed to collate avail-
able data on paediatric IBD (PIBD) and SARS-CoV-2 globally and
to develop consensus statements for the management of PIBD
during the COVID-19 pandemic. The consensus process included
specialists in paediatric IBD from the Paediatric IBD Porto group of
European Society of Paediatric Gastroenterology, Hepatology, and
Nutrition (ESPGHAN).
METHODS
Following an open call to the members of the Paediatric IBD
Porto group of ESPGHAN, international experts were selected as
the writing group. In addition to Porto group members, external
paediatric experts from China (Y.H. and Y.Z.) and South Korea
(B.K.), being the first endemic areas, were invited to participate, as
well as a representative from the SECURE-IBD registry (M.K.).
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RESULTS
On the basis of the literature review, the initial global
experience described below and the practice surveys, 12 statements
were formulated and agreed upon by the writing group. Voting by
the 37 Porto-group members and the authors retained 10 of which
(Table 1), all endorsed with a consensus of at least 92%.
The Chinese Experience of Paediatric
Inflammatory Bowel Disease Management
During Corona Virus Disease 2019 Outbreak
A total of 917 confirmed and suspected paediatric cases of
COVID-19 were reported in the 19 Chinese paediatric gastroenter-
ology centres who participated in the survey (84% from Wuhan),
none had a diagnosis of IBD. Between January 20 and March 20,
233 PIBD children should had received scheduled infliximab
infusions, of whom 66 (28%) had their infusions delayed because
of the epidemic by 1 to 8 weeks (average delay 19.2 11.5 days)
and 2 (0.9%) discontinued infusions temporarily. Among the 66
patients with delayed infusions, 14 (21%) experienced a disease
exacerbation, of whom 10 (15%) required an admission (average
length of hospital stay 10.4 6.0 days). In comparison, only 17
children (1.2%) of the 1431 PIBD Chinese children had disease
exacerbation during that period because of other causes (including
poor compliance to therapy [n¼ 10], uncontrolled primary disease
[n¼ 5] and Clostridium infection [n¼ 2]).
The South Korean Experience of Paediatric
Inflammatory Bowel Disease Management
During Corona Virus Disease 2019 Outbreak
Among the 8,413 confirmed infections with SARS-CoV-2 in
South Korea as of March 18, 2020 (23), 87 (1.03%) were between 0
and 9 years, and 438 (5.2%) were in the age group 10 to 19 years;
none died. The proportion of patients 19 years or less with con-
firmed COVID-19 (6.2%) was much less than the proportion of the
country’s population as reported by the local statistics bureau (18%;
9,315,774 among 51,629,512).
In the city of Daegu and Gyeonsangbuk-do province, where
87% of the total South Korean COVID-19 infection cases have been
confirmed, there are 4 tertiary pediatric centres following in total
272 children with IBD. These centres continued following children
with IBD at the outpatient clinics with 297 face-to-face appoint-
ments and 52 remote consultations. During this 2-month period,
biologics and immunomodulators have been prescribed without
changes in doses or intervals in almost all children (99.3%). No
cases of COVID-19 infection have been reported in South Korean
children with IBD. Thirteen families (4.8%) have postponed their
anti-TNF treatment because of parental anxiety about the virus, of
whom 3 (23%) had worsening in their Crohn disease activity. The
median delay in scheduled anti-TNF administration in these
patients was 17 days (range 14–22 days).
Porto Group of European Society of Paediatric
Gastroenterology, Hepatology, and Nutrition
Practice During the Corona Virus Disease 2019
Outbreak
Of the current 35 members of the Porto group of ESPGHAN,
32 (91%) responded to the survey of their practice during the
COVID-19 outbreak, representing 32 PIBD referral centers in
Europe, Israel, and Canada. Some of the face-to-face visits have
Paediatric Porto Group Reporting System
A REDCap reporting system has been constructed to collect 
all COVID-19 cases among children with IBD in the 102 Porto 
group-affiliated paediatric IBD centres in Europe (and several 
beyond). We asked for cases with a virological confirmation of 
SARS-CoV-2, but to avoid reporting bias of the more severe cases 
we allowed also highly suspected cases when testing was not 
available as per local testing policy since several countries permit 
testing only those with evidence of pneumonia (eg, France and 
Spain). Nonetheless, the suspected cases were labelled and justified 
individually based on both typical symptoms and close contact with 
a confirmed case. A 7-day follow-up was required to ensure 
capturing of the disease severity. The registry included demographic 
questions as well as pre-infection IBD clinical explicit details, 
treatments, and outcomes. The ethics committee of Shaare Zedek 
Medical Center, Jerusalem, waived the need for approval, given the 
urgent need for reporting clinical experience and as the report was 
retrospective, anonymous, and without contacting patients. For the 
SECURE IBD cases, the UNC-Chapel Hill Office for Human 
Research Ethics has determined that storage and analysis of de-
identified data does not constitute human subjects research as 
defined under federal regulations (45 CFR 46.102 and 21 CFR 
56.102) and does not require IRB approval.
Porto Group Survey
A survey among members of the Porto Group on changes in 
common practice in this new situation was launched via online 
platform in March 22, 2020. Investigators working in 32 tertiary 
centers around Europe, Israel, and Canada completed the survey. 
Different topics related to how the centers have adapted to COVID-
19 outbreak were collected, both regarding therapeutic strategies 
and in the logistic organization of the PIBD units.
Chinese Survey
A questionnaire was sent on March 20, 2020 to 19 paediatric 
gastroenterology centers in China to evaluate the impact of COVID-
19 on the prognosis of IBD children. These centers were distributed 
across 15 cities including Shanghai, Beijing, Guangzhou, Shenz-
hen, Hangzhou, Chongqing, Chengdu, Wuhan, Changsha, Zhengz-
hou, Xi’an, Xiamen, Guiyang, Nanjing, and Shenyang, in total care 
for 1431 children with IBD.
South Korean Survey
A questionnaire was sent on March 19, 2020 to 4 tertiary 
centres in the metropolitan city of Daegu and in Gyeonsangbuk-do 
province where the majority of the total South-Korean COVID-19 
infection cases have been confirmed. Data regarding the changes in 
medication prescription by physicians, changes in hospital visits, 
medication administration, and disease exacerbation were collected 
since January 20, 2020, the date of the first COVID-19 occurrence 
in South Korea.
Statement Voting
On the basis of the above collective data and literature 
review, the writing group formulated guidance points, which were 
sent to all members of the Porto group of ESPGHAN for comments 
and electronic voting (Appendix). It has been decided a priori that 
consensus is reached by at least 80% of voters.
The underlying IBD remained generally stable during the infec-
tion and the IBD-related medications were not held in any of
the cases.
Experience of Corona Virus Disease 2019 and
Inflammatory Bowel Disease in Adults
Surveillance Epidemiology of Coronavirus Under Research
Exclusion (SECURE-IBD) is an international registry to monitor
and report on outcomes of COVID-19 occurring in IBD patients. As
of April 4, 2020, 264 adults and 11 children with confirmed
COVID-19 infection have been reported. Similar to the Porto group
cases, the 11 paediatric patients had mild course of COVID-19 and
did not require hospitalization (known clinical data of the first case
is added to Table 2). A total of 79 adult patients have been
hospitalised and 12 died, all older than the age 33 and 9 of whom
older than 65 years of age.
CONCLUSIONS
We provide the first document on the global impact of
SARS-CoV-2 infection on paediatric IBD to date, from which
we have generated guidance points for paediatric gastroenterolo-
gists in the era of this COVID-19 pandemic. The general message of
continuing current IBD treatments is supported by the Chinese and
South Korean experience reported here of 20% disease exacer-
bation in children whose infliximab infusions were delayed.
TABLE 1. Guidance points endorsed by the Paediatric Porto Group of ESPGHAN (37 voting experts)
Statements Consensus rate
1. IBD per-se does not currently seem to be a risk factor for acquiring SARS-CoV-2, nor for a more severe infection. 100%
2. For decreasing the risk of contracting SARS-CoV-2 in children with IBD, we recommend using the same measures as in the
local population during the pandemic (eg, good hand hygiene, avoiding contact with anyone with respiratory symptoms and
social distancing).
100%
3. When possible by local situation and resources, children should continue follow-up visits to ensure appropriate monitoring of
the disease. Remote telemedicine consultations, along with the use of surrogate markers of inflammation (fecal calprotectin,
C-reactive protein, patient-reported outcomes) may, however, be an alternative to face-to-face office visits during the
epidemic, especially for those in remission. The option of delaying visits should be considered on an individual basis.
97%
4. Active IBD disease should be treated according to the standard guidance PIBD protocols as before the epidemics, as the risk of
IBD complications in active IBD outweighs any risk of COVID-19 complications, especially in children.
97%
5. There is currently no concrete evidence that any of the IBD treatments increases the risk for acquiring SARS-CoV-2 or for a
more severe infection once infected. Therefore, uninfected children should generally continue their medical treatment,
including immunomodulators and biologic therapies, as the risk of a disease flare outweighs any estimated risk of SARS-CoV2
infection. This is especially true in children who have a much milder infection. Specific considerations are listed below.
97%
6. Corticosteroids can be used to treat disease relapses, but as always recommended in children, the drug should be weaned as
soon as possible. In Crohn disease, exclusive enteral nutrition should be preferred.
92%
7. The use of anti-TNFs should be continued at the regular intervals and doses. Infusion centers should minimize crowding and
implement screening procedures for suspected COVID-19.
97%
8. Switching from infliximab to adalimumab in a stable child should be discouraged unless impossible to provide intravenous
infusions, as the risk of disease exacerbation after such a switch has been documented in the clinical trial setting.
97%
9. There is no clear indication to stop IBD treatment during COVID-19 infection, also because of the typical prolonged effect of
IBD drugs. Nonetheless, we recommend suspending immunosuppressive treatment during an acute febrile illness until fever
subsides and the child returns to normal health, irrespective of the SARS-CoV-2 testing status. In case of positive SARS-CoV-2
testing in an asymptomatic child, the decision of therapeutic changes should be individualized. Mesalamine should never be
suspended.
100%
10. Elective surgeries and nonurgent endoscopies should be postponed during the epidemic. 97%
All statements are limited to children and are based on the emerging but limited data available upon March 2020; it is possible that statements may change as
data on PIBD and COVID-19 will accumulate. The following 2 statements did not receive consensus of the Porto group, and thus were removed: ‘‘Up to one-
third of patients with COVID-19 may present with gastrointestinal symptoms, mainly diarrhea or nausea. Therefore, these symptoms during an active infection
do not necessarily indicate a flare of the underlying IBD’’ and ‘‘In children with suspected symptoms of COVID-19, SARS-CoV2 testing is recommended
before any therapeutic change’’. COVID-19¼ corona virus disease 2019; IBD¼ inflammatory bowel disease; PIBD¼ paediatric inflammatory bowel disease.
been changed to remote visits in 97% of PIBD centers. Thirty 
centers (94%) tried to limit patients attending the hospital if not 
strictly needed (exceptions are flares, drug collection, or infusions). 
Postponing clinics except those experiencing flares or new diagno-
sis has been practiced by 40% of centres. Of the 32 centres, 31 
(97%) encourage their patients not to make any changes in current 
treatments in response to COVID-19; drug doses and infusion 
intervals were not changed and combination therapy was continued. 
Children requiring infusions (ie, infliximab, vedolizumab) contin-
ued with the same regimen. Twenty-nine centers (91%), including 
endemic areas in Europe, had no limitations in the administration of 
parenteral drugs. Other actions implemented in the various centers 
included facilitating drug administration to the patients (eg, modi-
fying pharmacy opening hours, and increasing the number of 
dispensed doses) and limiting or stopping nonurgent endoscopic 
procedures.
Paediatric Inflammatory Bowel Disease Cases
With Confirmed or Highly Suspected SARS-
CoV-2 Infection
Seven children with IBD and COVID-19 have been reported 
until March 26, 2020 by the 102 sites affiliated with the Paedi-
atric IBD Porto group of ESPGHAN (Table 2). All cases had a 
mild infection without the need for admission despite treatment 
with immunosuppressive medications, steroids, and/or biologics.
We provide the first case series of children with IBD who
have SARS-CoV-2 infection, all cases were mild despite being
treated with immunosuppressive medications. These reassuring
cases are supported by the lack of symptomatic disease among
children with PIBD cases in China and South Korea. As SARS-
CoV-2 infection is often asymptomatic in children, it is likely that
the true mild/minimal infection rate is higher than identified.
Among 171 Chinese children with COVID-19, nearly a quarter
had no symptoms (8). The reason for the milder infection course in
children, resulting in lower hospitalisation rate and mortality, is not
yet clear. Our observation of mild or minimal SARS-CoV-2 infec-
tion in children with IBD despite treatment with immunosuppres-
sive medications is further supported by observations in children
with liver disease on immunosuppression in Northern Italy where
only 3/700 were documented to have SARS-CoV-2 infection and
none with a severe course (12). The larger case series of adults
reported from the SECURE-IBD registry show that current out-
comes do not vary substantially from reports from the general
population infected with SARS-CoV-2. SECURE-IBD cases may
be biased towards more severe cases as only confirmed infections
have been reported and in many countries, asymptomatic and mild
infections are not tested for the virus by local policy. Careful
continuous monitoring of the data is needed to base future possible
adjustments to the current guidance.
On the basis of currently (March 2020) available limited data
presented here, we suggest the following: IBD children, with and
without immunosuppressive and biological therapy, do not seem to
carry a higher risk of SARS-CoV-2 infection, compared with the
general population. We can cautiously suggest that currently there
is no signal indicating worsening the COVID-19 course by IBD-
related treatment. On the other hand, the risk of inappropriate
management of IBD driven by the fear of the virus may have a
significant impact on the health of IBD patients as indicated by
increased flares with delayed therapy in China and South Korea.
Therefore, there is presently no justification to support adaptation of
therapies for children with IBD in the light of the currently ongoing
SARS-CoV-2 pandemic, especially in children who have in general
a more extensive and severe IBD on one hand and milder COVID-
19 course on the other. Managing disease relapses in this period in
epidemic areas can be difficult, thus it is crucial to advise patients to
maintain their therapies, particularly when in remission. These
interim conclusions may be adjusted in the future based on emerg-
ing data on COVID-19 in children with IBD.
QUALIFYING STATEMENT
ESPGHAN is not responsible for the practices of physicians
and provides guidelines and position papers as indicators of best
practice only. This guidance may be revised as necessary to account
for changes in technology, new data, or other aspects of clinical
practice. This guidance is intended to be an educational device to
provide information that may assist clinicians in providing care to
patients. They are not a rule and should not be construed as
establishing a legal standard of care or as encouraging, advocating,
requiring, or discouraging any particular treatment. Clinical deci-
sions in any particular case involve a complex analysis of the
patient’s condition and available courses of action. Therefore,
clinical considerations may require taking a course of action that
varies from the suggestions made as part of this guidance.
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